Business
CSPC secures USD 30m from AstraZeneca for siRNA renal disease platform collaboration
CSPC Pharmaceutical Group (HKEX: 01093) has received the USD 30 million upfront payment from AstraZeneca under their collaboration, option and license...
MapLight bags USD 150m after muscarinic schizophrenia Phase II win
San Francisco and Boston-based MapLight Therapeutics, Inc. (Nasdaq: MPLT) announced a USD 150 million private placement financing to fund two pivotal-stage...
Zentalis adds USD 80.5m as azenosertib nears pivotal test
San Diego-based Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced the pricing of an underwritten public offering of 23 million shares of common stock at USD...
Khartis bags USD 95m for oral challenger to Tepezza
Khartis Therapeutics has emerged from stealth with USD 95 million in total funding, including a USD 50 million Series B led by Forge Life Science Partners,...
IASO Bio acquires MediSix to expand CAR-T reach into T-cell malignancies
China-based IASO Biotechnology ("IASO Bio") has completed the acquisition of MediSix Therapeutics, a Singapore-based immune cell engineering company, adding...
ArriVent hands Allist Greater China rights to MUC16/NaPi2b ADC
Shanghai Allist Pharmaceuticals (SSE: 688578) has licensed exclusive Greater China rights to AST12608/ARR-002, a dual-targeting MUC16/NaPi2b tetravalent...
MSD's China Innovation Center taps InventisBio for small-molecule oncology
Merck & Co. (NYSE: MRK), operating as MSD outside the US and Canada, and China-based InventisBio Co., Ltd. (SSE STAR: 688382) signed a collaboration...
PTC, Lilly scoop up Sangamo gene therapies in bankruptcy auction
Richmond, California-based Sangamo Therapeutics (OTC: SGMOQ) has concluded a court-supervised Section 363 asset auction, selecting Eli Lilly and Warren, New...
Boulevard Bio launches with Deerfield backing for IgAN pipeline
New York-based Boulevard Bio has emerged from stealth with USD 65 million in launch financing from Deerfield Management and affiliates, backed by early...
Zealand cashes out rusfertide royalty for USD 100m ahead of FDA decision
Copenhagen-based Zealand Pharma (Nasdaq: ZEAL) has agreed to sell its economic interests in rusfertide (PTG-300) to Royalty Pharma (Nasdaq: RPRX) for USD...
Merck KGaA partner Remepy raises USD 36m Series A for 'hybrid drug' platform
Israel-based Remepy, a biotechnology company developing Hybrid Drugs — a class that combines conventional prescription pharmaceuticals with personalized,...
UC Irvine alopecia spinout Amplifica gets Lilly backing in USD 26m Series B
San Diego-based Amplifica Holdings Group, Inc., a clinical-stage biopharmaceutical company developing injectable therapies for androgenetic alopecia (AGA),...
InduPro raises USD 77m as proximity-guided bispecific ADC enters clinic
Seattle-based InduPro, Inc. has closed a USD 77 million Series B financing and dosed the first patient in a Phase I study of IDP-001, a bispecific...
Silence upsizes USD 175m offering after divesiran Phase II win
UK-based Silence Therapeutics plc (Nasdaq: SLN) announced the pricing of an upsized underwritten public offering of American Depositary Shares (ADSs),...
Beyang bags USD 30m for AI-designed retinal, leukemia drugs
Shanghai-based Beyang Therapeutics Co., Ltd. has closed an oversubscribed USD 30 million Series A financing round to advance its AI-driven drug discovery...
The AllSci Brief
Free, systematic R&D and deal news. Daily.